Krystal Biotech Files 8-K on Security Holder Votes
Ticker: KRYS · Form: 8-K · Filed: May 21, 2024 · CIK: 1711279
| Field | Detail |
|---|---|
| Company | Krystal Biotech, Inc. (KRYS) |
| Form Type | 8-K |
| Filed Date | May 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Krystal Biotech filed an 8-K for shareholder votes. Nothing else to see here.
AI Summary
Krystal Biotech, Inc. filed an 8-K on May 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or outcomes, but it serves as an official record of the company's compliance with reporting requirements.
Why It Matters
This filing indicates that Krystal Biotech held a meeting where security holders voted on certain matters, which is a standard corporate governance procedure.
Risk Assessment
Risk Level: low — This is a routine filing related to corporate governance and does not appear to contain new material financial or operational information.
Key Players & Entities
- Krystal Biotech, Inc. (company) — Registrant
- May 21, 2024 (date) — Date of Report
- 2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 (address) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Krystal Biotech's security holders?
The filing does not specify the exact matters voted upon by security holders.
When was the earliest event reported in this 8-K filing?
The earliest event reported is May 21, 2024.
What is Krystal Biotech's principal executive office address?
Krystal Biotech's principal executive offices are located at 2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania 15203.
What is Krystal Biotech's IRS Employer Identification Number?
Krystal Biotech's IRS Employer Identification Number is 82-1080209.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-05-21 16:38:02
Filing Documents
- krys-20240521.htm (8-K) — 42KB
- 0001711279-24-000027.txt ( ) — 207KB
- krys-20240521.xsd (EX-101.SCH) — 2KB
- krys-20240521_def.xml (EX-101.DEF) — 10KB
- krys-20240521_lab.xml (EX-101.LAB) — 31KB
- krys-20240521_pre.xml (EX-101.PRE) — 20KB
- krys-20240521_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 17, 2024, Krystal Biotech, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Set forth below are the matters acted upon at the Annual Meeting and the final voting results on each matter. Proposal One: Election of Class I Directors The Company's stockholders elected Suma M. Krishnan, Julian S. Gangolli, and Catherine Mazzacco as members of the Company's Board of Directors as Class I directors for a three-year term. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Suma M. Krishnan 21,058,004 1,498,017 2,244,047 Julian S. Gangolli 17,226,067 5,329,954 2,244,047 Catherine Mazzacco 20,382,924 2,173,097 2,244,047 Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the vote were as follows: Votes For Votes Against Abstentions 24,769,838 7,438 22,792 Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2023, as disclosed in the Company's proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 21,697,311 851,690 7,020 2,244,047
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 21, 2024 KRYSTAL BIOTECH, INC. By: /s/ Krish S. Krishnan Name: Krish S. Krishnan Title: Chairman and Chief Executive Officer